The global lung cancer therapeutics market is anticipated to grow at a CAGR of around 8.7% during the forecast period. Lung cancer negatively affects the lungs' potential to deliver oxygen to the bloodstream. It is one of the most commonly diagnosed diseases, and among all cancers, lung cancer has the highest mortality rate in both men and women. The primary risk factor for the development of lung cancer is cigarette smoking. Further rise in the adoption of unhealthy lifestyles among people, growing demand for targeted therapies, and availability of efficient drugs and treatments are also propelling the growth of the market. On the contrary, widespread availability of only essential generic drugs, the presence of limited treatment options, and a large unmet need for diagnosis are expected to be the major factors restraining the overall growth of the lung cancer therapeutics market. However, the increasing rate of approvals in lung cancer therapeutics and the introduction to nanomedicine will be creating an opportunity for the growth of the market.

Free Sample Copy @ https://www.omrglobal.com/request-sample/lung-cancer-therapeutics-market

The global Lung Cancer Therapeutics market is segmented based on drugs, therapy, and end-user. Based on drugs, the market is segmented into Platinol, Taxol, Gemzar, Alimta, and others (Iressa, Hycamtin, Gilotrif, Taxotere, Xalkori). Based on therapy, the market is classified into chemotherapy, targeted therapy, immunotherapy, radiation therapy, and others. Further, based on end-user, the market is segregated into multispeciality hospitals and cancer research centers.

A Full Report of Global Lung Cancer Therapeutics Market is Available at:
https://www.omrglobal.com/industry-reports/lung-cancer-therapeutics-market

The global lung cancer therapeutics market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. Due to a high prevalence rate of lung cancer in the region, North America is projected to have a significant share in the global market. For instance, according to the American Lung Association, lung cancer has been diagnosed in approximately 541,000 Americans at some point in their lives. An estimated 234,030 new cases of lung cancer were expected to be diagnosed in 2018, accounting for roughly 13% of all cancer diagnoses. Furthermore, targeted therapies are a rapidly expanding area of cancer research, with researchers studying numerous new targets and drugs in clinical trials, therefore these factors are propelling the market growth in North America.

Global Lung Cancer Therapeutics Market – Segmentation
by Drugs
Platinol
Taxol
Gemzar
Alimta
Others (Iressa, Hycamtin, Gilotrif, Taxotere, Xalkori)
by Therapy
Chemotherapy
Targeted Therapy
Immunotherapy
Radiation Therapy
Others
by End-User
Multispeciality Hospitals
Cancer Research Centers

Global Lung Cancer Therapeutics Market – Segmentation by Region 
North America 
United States
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific 
China
Japan
India
Rest of Asia-Pacific
Rest of the World

Company Profiles
Abbvie Inc.
Achieve Life Sciences, Inc.
Amgen Inc.
AstraZeneca Plc
Astellas Pharma Inc.
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co.
Celldex Therapeutics, Inc
Eisai Co Ltd
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd.
Glaxosmithkline Plc
Helsinn Healthcare S.A.
Novartis International AG
Pfizer, Inc.
Sanofi SA
Teva Pharmaceutical Industries Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/lung-cancer-therapeutics-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected] 
Contact no: +91 780-304-0404